Brain Cancer Therapeutics Market Analysis & Forecast: 2026-2033
The global brain cancer therapeutics market size is estimated to reach USD 4,052 Mn in 2026 and is projected to grow at a CAGR of 9.8% during the forecast period (2026-2033), surpassing USD 7,796.3 Mn by 2033. This growth is attributable to rising incidence of brain tumors, increasing adoption of targeted therapies as well as immunotherapies, and advancements in diagnostic and treatment technologies. More than 1.3 million Americans are living with a primary brain tumor, of which approximately 74% are benign and 26% are malignant, while females account for nearly 59% of all diagnosed cases.
The global brain cancer therapeutics market is projected to register robust growth during the forecast period. This is primarily due to rising burden of brain tumors, increasing demand for targeted therapies, growing investments in oncology research, and expanding clinical trials for innovative treatment options. Continuous advancements in diagnostic technologies are also supporting market expansion.
Expansion of immunotherapy and novel treatment approaches is expected to support market expansion during the forecast period. Immunotherapies such as checkpoint inhibitors and CAR-T therapies are increasingly used for difficult brain tumors, opening new treatment pathways and expanding the market.
Advancements in brain cancer therapies are also driving market growth. Leading pharmaceutical companies and research institutes are developing novel therapies for brain cancer treatment. For instance, in May 2026, researchers at
Similarly, Kopra Bio, a biotechnology startup spun out of the University of California, San Francisco, raised $9.1 million in June 2026 to advance its genetically engineered viral therapy for glioblastoma. The company will inject the investigational therapy into glioblastoma patients in a Phase I clinical trial in China. These developments are expected to support the growth of the brain cancer therapies market during the forecast period.
According to Coherent Market Insights’ latest brain cancer therapeutics market analysis, glioblastoma is set to lead the market, accounting for a 50% share in 2026. This dominance is attributable to its high incidence among malignant primary brain tumors, poor prognosis requiring aggressive treatment, high recurrence rates, and the increasing adoption of advanced therapies such as targeted therapies, immunotherapies, and tumor-treating fields.
Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults. It accounts for around 50% of all primary central nervous system malignancies, creating strong demand for brain cancer therapeutics. Continuous clinical research, expanding clinical trials, and growing investments in novel glioblastoma treatments are also set to boost segment growth during the forthcoming period.
To learn more about this report, Request Free Sample
Based on treatment type, targeted therapy is expected to dominate the market, accounting for a share of 35% in 2026. This is mostly due to its ability to precisely target cancer cells while reducing damage to healthy tissues, resulting in better treatment outcomes and fewer side effects than conventional chemotherapy.
Growing popularity of biomarker-based diagnostics, rising approvals of new targeted drugs and personalized medicines are other factors fueling the demand. Similarly, ongoing clinical trials evaluating novel targeted agents for aggressive brain tumors such as glioblastoma are expanding treatment options as well as strengthening the market position of targeted therapies.
For example, a 2025 phase 1/2 umbrella trial evaluated molecularly matched targeted therapies in 228 newly diagnosed glioblastoma patients, highlighting the growing adoption of precision medicine. Such advancements are expected to support expansion of the targeted therapy segment during the forecast period.
Increasing global burden of brain tumors is providing a strong impetus for the growth of brain cancer therapeutics market. There is a steady rise in cases of brain cancers globally. For instance, approximately 321,000 new cases of brain and other CNS tumors were reported worldwide based on the latest global estimates. This rising disease incidence is expected to propel demand for brain cancer therapeutics over the forecast period.
Increasing adoption of targeted therapies is a key growth-shaping trend in the brain cancer therapeutics market. Treatment approaches are shifting from traditional chemotherapy to biomarker-based targeted therapies that act on specific genetic mutations in tumors. This improves treatment outcomes as well as reduces side effects.
Rising adoption of combination therapies is another market trend. In contemporary clinical practice, physicians are increasingly using multiple approaches together, including surgery, radiation therapy, chemotherapy, and immunotherapy, to improve patient outcomes. This rising use of combination therapies is expected to boost overall brain cancer therapeutics market value during the forthcoming period.
|
Current Event |
Description and its Impact |
|
FDA Approval of the First Drug for Diffuse Midline Glioma (2025) |
|
|
More Than 310 Brain Tumor Clinical Trials Active Worldwide (2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America is expected to account for a prominent share of around 40% in the global brain cancer therapeutics market in 2026. This is attributable to the high incidence of brain and central nervous system (CNS) tumors, advanced oncology infrastructure, and early adoption of targeted therapies and immunotherapy-based treatment approaches. Strong clinical trial activity and widespread access to advanced diagnostics such as MRI and molecular profiling are also supporting market expansion.
Rising burden of brain tumors is acting as a catalyst for the growth of the North America brain cancer therapeutics market. According to the National Cancer Institute, there were approximately 24,820 new cases of brain and other nervous system tumors in the United States in 2025. This rising incidence is expected to fuel demand for brain cancer therapeutics in the region during the forecast period.
Asia Pacific is anticipated to emerge as a highly lucrative market for manufacturers of brain cancer therapeutics during the forecast period, registering a CAGR of 11%. This is mainly due to the rising cancer burden, improving access to neurology and oncology care, and growing adoption of advanced diagnostic imaging and targeted therapies. Expansion of healthcare infrastructure and increasing awareness about early cancer detection are also supporting treatment uptake in the region.
Increasing incidence of brain and central nervous system (CNS) tumors and improving diagnostic reach are boosting the Asia Pacific brain cancer therapeutics market. According to the American Society of Clinical Oncology, Asia Pacific accounts for nearly 50% of global cancer cases. This, in turn, is increasing demand for surgical and pharmacological brain cancer treatments.
The United States is expected to remain a leading market for brain cancer therapies throughout the forecast period. This can be attributed to presence of advanced oncology infrastructure, rising adoption of targeted therapies and immunotherapies, and a high rate of clinical research activity. Early availability of innovative drugs and rising use of advanced diagnostic tools such as MRI and molecular profiling, which improve early detection and treatment outcomes, are also boosting sales growth in the nation.
An increase in the prevalence of brain tumors is expected to drive growth in the U.S. brain cancer therapeutics market over the forecast period. For instance, according to the American Association of Neurological Surgeons (AANS), about 200,000 new cases of brain metastases are diagnosed in the United States each year, and this number is expected to increase with improved diagnostic techniques and greater clinical awareness.
The brain cancer therapeutics market in China is projected to witness strong growth, owing to a large patient pool, improving access to advanced oncology care, and expanding healthcare infrastructure. Increasing awareness of early cancer diagnosis and growing availability of neurosurgical and targeted treatment options are also supporting market growth in the country.
Some of the major players in brain cancer therapeutics market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson, Merck & Co, Bayer AG, and Bristol-Myers Squibb Company.
Top manufacturers of interventional pulmonary devices are adopting various organic and inorganic strategies to boost their sales as well as gain a competitive edge over the industry. These include new product launches and approvals, investments in R&D, clinical trials, mergers, acquisitions, distribution agreements, partnerships, collaborations, and joint ventures.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4,052 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.8% | 2033 Value Projection: | USD 7,796.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson, Merck & Co, Bayer AG, and Bristol-Myers Squibb Company |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
